PT1420769E - Modulação de perfil lipídico com esteróides e agonistas de ppar alfa - Google Patents

Modulação de perfil lipídico com esteróides e agonistas de ppar alfa Download PDF

Info

Publication number
PT1420769E
PT1420769E PT02707001T PT02707001T PT1420769E PT 1420769 E PT1420769 E PT 1420769E PT 02707001 T PT02707001 T PT 02707001T PT 02707001 T PT02707001 T PT 02707001T PT 1420769 E PT1420769 E PT 1420769E
Authority
PT
Portugal
Prior art keywords
steroids
lipid profile
ppar alpha
alpha agonists
profile modulation
Prior art date
Application number
PT02707001T
Other languages
English (en)
Inventor
Nicholas M Morton
Jonathan Robert Seckl
Brian Robert Walker
Ruth Andrew
Original Assignee
Univ Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Edinburgh filed Critical Univ Edinburgh
Publication of PT1420769E publication Critical patent/PT1420769E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PT02707001T 2001-03-23 2002-03-25 Modulação de perfil lipídico com esteróides e agonistas de ppar alfa PT1420769E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0107383.2A GB0107383D0 (en) 2001-03-23 2001-03-23 Lipid profile modulation

Publications (1)

Publication Number Publication Date
PT1420769E true PT1420769E (pt) 2008-08-05

Family

ID=9911465

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02707001T PT1420769E (pt) 2001-03-23 2002-03-25 Modulação de perfil lipídico com esteróides e agonistas de ppar alfa

Country Status (12)

Country Link
US (1) US20050032761A1 (pt)
EP (1) EP1420769B1 (pt)
JP (1) JP2004528308A (pt)
AT (1) ATE397922T1 (pt)
AU (1) AU2002241160A1 (pt)
CA (1) CA2441834C (pt)
DE (1) DE60227080D1 (pt)
DK (1) DK1420769T3 (pt)
ES (1) ES2307729T3 (pt)
GB (2) GB0107383D0 (pt)
PT (1) PT1420769E (pt)
WO (1) WO2002076435A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258168B2 (en) 2001-07-27 2007-08-21 Enventure Global Technology L.L.C. Liner hanger with slip joint sealing members and method of use
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
US7501405B2 (en) 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
EP1854487A3 (en) * 2003-04-11 2010-09-22 High Point Pharmaceuticals, LLC Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
EP1615667A2 (en) * 2003-04-11 2006-01-18 Novo Nordisk A/S Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
ATE416761T1 (de) * 2003-09-22 2008-12-15 Onepharm Res & Dev Gmbh Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
WO2006106052A1 (en) 2005-04-05 2006-10-12 F. Hoffmann-La Roche Ag Pyrazoles
US7622492B2 (en) 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
WO2007058346A1 (ja) 2005-11-21 2007-05-24 Shionogi & Co., Ltd. I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物
AU2007207055B2 (en) 2006-01-18 2011-06-02 F. Hoffmann-La Roche Ag Thiazoles as 11 beta-HSD1 inhibitors
JP2009531712A (ja) * 2006-03-23 2009-09-03 デ グスマン ブレイヤー、エメリタ アポリポタンパク質フィンガープリント技術
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
DK2163543T3 (en) 2007-05-18 2015-04-27 Shionogi & Co Nitrogenholdigt heterocyklisk derivat med 11beta-hydroxysteroiddehydrogenase-type 1-inhibitorisk aktivitet
MX2011005037A (es) 2008-11-21 2011-06-16 High Point Pharmaceuticals Llc Compuestos de adamantilo benzamida.
WO2011061749A2 (en) * 2009-11-19 2011-05-26 Ganga Raju Gokaraju Agents derived from holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
US9781909B2 (en) * 2013-07-17 2017-10-10 University Of Manitoba Mito-Ob: a transgenic mouse model for obesity
FR3035326B1 (fr) * 2015-04-21 2017-05-12 Pf Medicament Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique
US10226474B2 (en) * 2017-01-09 2019-03-12 Temple University—Of The Commonwealth Sytem Of Higher Education Methods and compositions for treatment of non-alcoholic steatohepatitis
KR102177304B1 (ko) * 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
CN113329754A (zh) 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
AU2023273030A1 (en) 2022-05-16 2024-11-07 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518595A (en) * 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
US4920115A (en) * 1988-12-28 1990-04-24 Virginia Commonwealth University Method of lowering LDL cholesterol in blood
GB9517622D0 (en) * 1995-08-29 1995-11-01 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
US5985861A (en) * 1996-11-04 1999-11-16 Columbia Laboratories, Inc. Progesterone for treating or reducing ischemia
US7045513B1 (en) * 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
JP2004502432A (ja) * 2000-07-05 2004-01-29 バイエル アクチェンゲゼルシャフト ヒト11β−ヒドロキシステロイドデヒドロゲナーゼ1様酵素の調節
GB0105772D0 (en) * 2001-03-08 2001-04-25 Sterix Ltd Use

Also Published As

Publication number Publication date
EP1420769A2 (en) 2004-05-26
GB2390367A (en) 2004-01-07
CA2441834C (en) 2011-01-25
JP2004528308A (ja) 2004-09-16
DE60227080D1 (de) 2008-07-24
WO2002076435A2 (en) 2002-10-03
US20050032761A1 (en) 2005-02-10
GB0107383D0 (en) 2001-05-16
WO2002076435A3 (en) 2004-03-18
DK1420769T3 (da) 2008-09-29
EP1420769B1 (en) 2008-06-11
GB2390367B (en) 2005-04-13
ATE397922T1 (de) 2008-07-15
CA2441834A1 (en) 2002-10-03
ES2307729T3 (es) 2008-12-01
GB0323962D0 (en) 2003-11-19
AU2002241160A1 (en) 2002-10-08

Similar Documents

Publication Publication Date Title
DK1420769T3 (da) Lipid profil modulation med steroider og PPAR alpha agonister
BR0215405A (pt) Composições e processos de uso de collajolie
ECSP055838A (es) Formulaciones de deposito de liberacion controlada
MY139142A (en) Short corridor progressive addition lenses with reduced unwanted astigmatism
MY144626A (en) Semiconductor-nanocrystal/conjugated polymer thin films
EP1700120A4 (en) MARKER FOR OPTICAL NEUROMYELITIS
NO20015785D0 (no) I dets vesentlige oljefrie cyklosporinsammensetninger
GB2395253B (en) Internet refrigerator with web pad and method for operating the same
PH12022552267A1 (en) Tie2-binding agents and methods of use
ITRM20020105A0 (it) Dispersione poliuretanica con elevata durezza della pellicola, procedimento per la sua preparazione e suo impiego.
WO2003102012A3 (en) New etonogestrel esters
GB0011358D0 (en) Novel use
FR2845917B1 (fr) Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
IL162862A0 (en) Short-acting sedative hypnotic agents for anesthesia and sedation
CY1105009T1 (el) Συνθεση καχαλαλιδης f
ITMI20021822A1 (it) Manicotto elastico e procedimento per la fabbricazione di un manicotto elastico
BR9913073B1 (pt) agente anti-ultra-violeta para composiÇço de borracha, composiÇço de borracha À base de pelo menos um elastâmero, e, artigo acabado.
MY135452A (en) 2-methyl-thieno-benzodiazepine lyophilized formulation
FI20031191A7 (fi) Monoamiinin takaisinoton estäjä
IL173929A0 (en) Analogues of kahalalide f and pharmaceutical compositions containing the same
AU2003285485A1 (en) 5 ANDROSTEN-3Beta-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
MXPA04007387A (es) El empleo de inhibidores del intercambiador de sodio/hidrogeno para el tratamiento de desordenes tromboticos e inflamatorios.
TW200500012A (en) Novel lactobacillus and use thereof
TW200507005A (en) Assembly for lamp construction and associated lamp and method for connecting the assembly
CA96910S (en) Flag